HCV resistance testing in clinical practice. Daniel Bradshaw Virus Reference Department National Infection Service Public Health England
|
|
- Brandon Webb
- 5 years ago
- Views:
Transcription
1 HCV resistance testing in clinical practice Daniel Bradshaw Virus Reference Department National Infection Service Public Health England
2 Declaration of Interests Dan Bradshaw has received personal grants for research from Janssen and Viiv Pharmaceuticals. 2 HCV resistance testing in clinical practice
3 Overview 1. Introduction 2. Genotypic susceptibility testing 3. Clinical interpretation of resistance mutations 4. Impact of resistance on specific DAA regimens DAA naïve DAA experienced 5. Case study 3 HCV resistance testing in clinical practice
4 1. Introduction 4 HCV resistance testing in clinical practice
5 HCV direct-acting antiviral agents 5 HCV resistance testing in clinical practice
6 Phylogenetic trees for HCV and HIV-1 6 HCV resistance testing in clinical practice Klenerman et al PLoS Med :e
7 % Prevalence of resistance-associated substitutions (RAS), PHE Colindale, Naïve DAA Experienced / / / / /115 NS3 NS5A NS5B /102 7 HCV resistance testing in clinical practice
8 2. Genotypic susceptibility testing 8 HCV resistance testing in clinical practice
9 Sanger Sequencing HCV RNA dntp ddntp DNA polymerase Primer RT-PCR PCR amplification dsdna strand separation cdna PCR amplicon ssdna Primer annealing, dntp incorporation & strand elongation Chain termination with fluorescent ddntp Adapted from Fraher et al Nat Rev Gastroenterol Hepatol 9: Reading of chromatograph & comparison to database
10 Next Generation Sequencing 10 HCV resistance testing in clinical practice Mbisa & Tedder RCPath Bulletin
11 11 HCV resistance testing in clinical practice Clinical interpretation tool
12 Investigation of treatment failure with sequencing 12 HCV resistance testing in clinical practice Midgard et al J Hep 65: S
13 HCV genotype 2k/1b chimeras 13 HCV resistance testing in clinical practice Susser et al J Hep 67:
14 3. Clinical interpretation of RAS 14 HCV resistance testing in clinical practice
15 Clinical interpretation of HCV RAS Viral Genotype / subtype Viral load Fitness Effect in vitro Patient Treatment history Fibrosis stage Regimen Drug potency Genetic barrier to resistance Regimen composition 15 HCV resistance testing in clinical practice
16 Global HCV genotype distribution 16 HCV resistance testing in clinical practice Messina et al Hepatology 61:
17 HCV Genotypes in the UK : different in HIV patients General UK population HIV positive population G1 G4 G3 G1 G2 G3 G4 G1 Slide from G Cooke 17 HCV resistance testing in clinical practice
18 SHARED Study 18 HCV resistance testing in clinical practice Gupta et al EASL PS-090 Paris 2018
19 Prevalence of S282T in patients failing a SOF-containing regimen 19 HCV resistance testing in clinical practice Fourati et al Hepatology doi:
20 Predicted impact of RAS on NS5A inhibitors 20 HCV resistance testing in clinical practice Gottwein et al Gastroenterology154:
21 Clinically important RAS: IDSA / AASLD 2017 Ledipasvir/sofosbuvir Elbasvir/grazoprevir Genotype 1a 1b 3 Q30H/R L31V NA L31M/V Y93H Y93C/H/N M28A/T Y93H NA Q30H/R L31M/V Y93C/H/N Sofosbuvir/velpatasvir NA NA Y93H 21 HCV resistance testing in clinical practice
22 Clinically relevant NS5A resistanceassociated substitutions (RAS) Presentation title - edit in Header and Footer Sorbo et al Drug Resist Update 37:
23 Clinical decision-making No impact Presence of RAS Avoid regimen Prolong therapy Add ribavirin 23 HCV resistance testing in clinical practice
24 o 15 members: PHE HCV Resistance Group Community representative Working document: use of resistance testing to guide therapy o o o o o Epidemiologist Hepatologists ID physicians HIV physicians Virologists Clinical development of GLUE interpretative algorithm Development of collaborative scientific proposals 24 HCV resistance testing in clinical practice
25 4. RAS impact on specific DAA regimens DAA-naïve patients 25 HCV resistance testing in clinical practice
26 100 Efficacy of SOF/LDV in therapy-naive GT1a patients with and without cirrhosis: pooled analysis % SVR weeks 12 weeks ION 1-3 Lonestar 1 Electron / / 365 Nil BL RAS 12 / / 28 BL RAS < 100 FC 24 / / 47 BL RAS > 100 FC Sarrazin et al Gastroenterol 151: HCV resistance testing in clinical practice
27 SVR12 rate (%) UK National Registry: Genotype 1a Non-cirrhotic Treatment Elbasvir-Grazeprevir Number No fibrosis Mild fibrosis Moderate fibrosis of patients: Elbasvir-Grazeprevir and Ribavirin Paritaprevir-Ombitasvir, Dasabuvir Paritaprevir-Ombitasvir, Dasabuvir and Ribavirin Sofosbuvir-Ledipasvir Sofosbuvir-Ledipasvir and Ribavirin Drysdale K, Foster GR et al.. BASL, York, UK Queen Mary University of London
28 SVR12 rate (%) 100 UK National Registry: Genotype 1a Cirrhotic Treatment 95 Elbasvir-Grazeprevir Elbasvir-Grazeprevir and Ribavirin Paritaprevir-Ombitasvir, Dasabuvir Paritaprevir-Ombitasvir, Dasabuvir and Ribavirin Sofosbuvir-Ledipasvir 75 Sofosbuvir-Ledipasvir and Ribavirin 70 Compensated cirrhosis Decompensated cirrhosis Number of patients Drysdale K, Foster GR et al.. BASL, York, UK Queen Mary University of London
29 SVR12 (%) SVR12 in HCV genotype 1a infected patients treated with elbasvir / grazoprevir Any ELB RAS No ELB RAS 20 C-Surfer C-Edge TN C-Edge coinf C-Edge TE C-Worthy C-Salvage 0 441/450 39/56 132/133 11/18 56/56 5/9 67/67 6/6 All 12W no RBV All 12W + RBV 16 or 18W no RBV 16 or 18W + RBV Komatsu et al Gastroenterology 152: HCV resistance testing in clinical practice
30 % SVR Impact of NS5A RAS on SOF/VEL in genotype 3a Astral 1-3, 5 Polaris 2&3 411/420 53/57 19/22 4/6 No RAS Any RAS Y93H Cirrhosis + Y93H Hezode et al J Hep 68: HCV resistance testing in clinical practice
31 % S V R SVR12 for 255 GT1-infected patients with decompensated cirrhosis on SOF/VEL NS5A RAS No NS5A RAS 0 SOF/VEL/RBV 12 SOF/VEL 12 SOF/VEL 24 Astral-4 Curry et al NEJM 373: HCV resistance testing in clinical practice
32 Outcomes of therapy with GLE/PIB in GT3a and NS5A RAS No cirrhosis Cirrhosis %SVR12 Rx naïve Rx exp Rx naïve Rx exp 8 weeks 12 weeks 12 weeks 16 weeks 12 weeks 16 weeks A30K 78 (14/18) 93 (13/14) 25 (1/4) 0 (0/1) 1 (1/1) - No A30K 99 (161/163) 99 (241/243) 96 (43/45) 100 (20/20) 100 (62/62) 94 (48/51) Y93H 100 (10/10) 91 (10/11) 50 (2/4) (5/5) 100 (1/1) No Y93H 97 (165/171) 99 (244/246) 93 (42/45) 95 (20/21) 100 (58/58) 94 (47/50) Surveyor-1,2 Endurance 1-4 Expedition 1 & 4 Krishnan et al AAC pii: HCV resistance testing in clinical practice
33 SVR12 rate (%) UK National Registry: Genotype 3 Non-cirrhotic No fibrosis Mild fibrosis Moderate fibrosis Number of patients Treatment Glecaprevir-Pibrentasvir Sofosbuvir-Velpastasvir Sofosbuvir-Velpatasvir and Ribavirin Sofosbuvir, Daclatasvir Sofosbuvir, Daclatasvir and Ribavirin Drysdale K, Foster GR et al.. BASL, York, UK Queen Mary University of London
34 Resistance testing recommendations: IDSA / AASLD 2017 Regimen GT Rx Hx Elbasvir / grazoprevir 1a TN, TE Sofosbuvir / ledipasvir 1a TE Sofosbuvir / velpatasvir 3 TN (c), TE Sofosbuvir / daclatasvir 3 TN (c), TE 34 HCV resistance testing in clinical practice C cirrhosis, TN treatment naïve, TE (P/R) treatment experienced
35 NHS England rate card (from April 2018) 35 HCV resistance testing in clinical practice Possible role for RAS testing
36 DAA-experienced patients 36 HCV resistance testing in clinical practice
37 12 weeks of sofosbuvir, velpatasvir and voxilaprevir in DAA experienced patients: integrated resistance analysis from phase 3 studies 98% SVR12 NS5A RAS 39% (164/417) NS3+NS5A RAS 18% (76/417) 98% SVR12 282/288 NS3 RAS 12% (48/417) Surveillance of resistance to HCV NS5A inhibitors 37 HCV resistance testing in clinical practice No RAS 31% (129/417) 127/129 POLARIS-1 & POLARIS-4 Deep sequencing with 15% cut off Sarrazin et al THU-248 EASL 2017
38 MAGELLAN-1 Study, Part 2: glecaprevir / pibrentasvir in genotype 1 or 4 with failure to DAA regimen % (77-100) No RASs 100 NS3 only 83 (64-93) NS5A only Breakthrough 1 0 Relapse NS3 + NS5A 38 HCV resistance testing in clinical practice % (77-100) (79-99) No RASs NS3 only NS5A only 25 4 NS3 + NS5A Poordad et al Hepatology 67:
39 Retreatment of HCV infection in patients who failed GLE/PIB with SOF/GLE/PIB + RBV: MAGELLAN-3 study SVR12 (% patients) Arm A, n=2 Arm B, n=21 SVR12 SVR12 Week Treatment arm Cirrhosis Genotype status A 1, 2, 4, 5, 6 NC No B 3 Any Any B Any C Any B Any Any Yes Prior NS5Ai and/or PI* Arm A Arm B Total 39 HCV resistance testing in clinical practice Wyles D, et al, ILC #PS
40 5. Case example 45 year old MSM HIV-1/HCV coinfection Wales CD4 465 (28%) c/mm 3 HIV RNA < 40 c/ml Raltegravir/Truvada HCV genotype 3a HCV RNA 6.1 log IU/mL ALT 131 U/L Fibroscan 12.1 kpa Therapy-naive Nil co-meds Prior IDU nil in 2 years Occasional chems 40 HCV resistance testing in clinical practice
41 Baseline Sanger sequencing Genotype 3a NS5A: A30K 41 HCV resistance testing in clinical practice
42 7 6 GLE/PIB 12 wk post EOT HCV RNA log IU/mL ND Weeks 42 HCV resistance testing in clinical practice
43 Whole genome sequencing Genotype 3a NS3: nil RAS NS5A: A30K + Y93H NS5B: nil RAS 43 HCV resistance testing in clinical practice
44 In vitro fold change in EC50 vs wild type for NS5A RAS in HCV genotype 3a A30K Y93H A30K + Y93H Velpatasvir Pibrentasvir HCV resistance testing in clinical practice 1. Hezode et al J Hep 68: Cheng et al EASL Poster Lawitz et al AAC 60: Krishnan et al AAC doi:
45 Management plan Adherence support? SOF / VEL / VOX +/- RBV? SOF / GLE / PIB +/- RBV 45 HCV resistance testing in clinical practice
46 16 weeks of SOF/GLE/PIB + RBV in genotype 3: Magellan-3 46 HCV resistance testing in clinical practice Lok A, et al. ILC LBO
47 Re-treatment program 5-10%? % DAA virologic failure SOF/VEL/VOX 1 SVR 90-95% SVR 1. NHS retreatment option following nonresponse to any DAA except TPV or BOC next generation sequencing 2 2. HCV Research UK or Public Health England Presentation title - edit in Header and HCV resistance testing in clinical practice Footer
48 Summary RAS testing may be used to support treatment decisions in some circumstances Other treatment strategies without RAS testing often likely to be effective eg where rapid initiation of therapy is critical or no access to RAS testing Key groups for RAS testing: 1. GT1a prior to ELB/GZR 2. GT3a with cirrhosis prior to SOF/VEL 3. All GT with decompensated cirrhosis 4. All rare genotypes and subtypes 5. All GT with NS3 and/or NS5A inhibitor experience prior to re-treatment 48 HCV resistance testing in clinical practice
49 Acknowledgements Antiviral Unit, Virus Reference Department, PHE PHE HCV Resistance Group Tamyo Mbisa David Bibby Carmen Manso Hodan Mohamed Adriana Alvarez Juan Ledesma Renata Piorkowska Yuen Chan Nigel Wallis Ayodele Osobu Laura Bubba Ellie Barnes Will Irving Graham Foster Graham Cooke Anna Maria Geretti David Mutimer Caroline Sabin Brendan Healy Emma Thomson Kosh Agarwal Tamyo Mbisa John McLauchlan Charles Gore Rachel Halford Ras Smit Peter Moss 49 HCV resistance testing in clinical practice
50 SVR4 (%) BACK UP SLIDE Phase 3b study of GLE/PIB ± RBV in GT 1 HCV subjects previously treated with an NS5A inhibitor + SOF therapy Non-cirrhotics (2:1 arm A:B) Cirrhotics (1:1 arm C:D) Arm A Arm B Arm C Arm D GLE/PIB GLE/PIB GLE/PIB + RBV GLE/PIB SVR12 SVR12 SVR12 SVR12 Week Treatment period Post-treatment period Arm C enrollment 86 2 relapse stopped 2/19/18 1 BT 1 relapse 3 BT GLE/PIB x12 weeks GLE/PIB x16 weeks GLE/PIB + RBV x12 weeks GLE/PIB x16 weeks GLE, glecaprevir; PIB, pibrentasvir; RBV, ribavirin; SOF, sofosbuvir; BT, breakthrough Lok A, et al. ILC #LBO HCV resistance testing in clinical practice
Cases: Management of Hepatitis C in Prior Treatment Failure
Cases: Management of Hepatitis C in Prior Treatment Failure David L. Wyles, MD Professor of Medicine University of Colorado Chief, Division of Infectious Disease Denver Health Learning Objectives After
More informationHCV Resistance Clinical Aspects. Sanjay Bhagani Royal Free Hospital/UCL London
HCV Resistance Clinical Aspects Sanjay Bhagani Royal Free Hospital/UCL London DAAs in 2018, and beyond % patients % patients Changing characteristics of patients treated with DAA over time Prospective,
More informationManagement of HCV in Prior Treatment Failure
Management of HCV in Prior Treatment Failure Arthur Y. Kim, MD Associate Professor of Medicine Harvard Medical School Boston, Massachusetts Learning Objectives After attending this presentation, learners
More informationViva La Revolución: Options to Combat Hepatitis C
Viva La Revolución: Options to Combat Hepatitis C David L. Wyles, MD Professor of Medicine University of Colorado Chief, Division of Infectious Disease Denver Health Learning Objectives After attending
More informationDisclosures. Advanced HCV management. Overview. Renal failure 1/10/2018. Research Grant support to UCSF from AbbVie Gilead Merck Proteus NIH
Disclosures Advanced HCV management Annie Luetkemeyer, MD Division of HIV, ID and Global Medicine ZSFG, UCSF Research Grant support to UCSF from AbbVie Gilead Merck Proteus NIH Overview Renal failure Acute
More information2017 Bruce Lucas Hepatology and Liver Transplant Symposium October 13th 2017 Management of Hepatitis C in Pre- and Post-Transplant Patients
2017 Bruce Lucas Hepatology and Liver Transplant Symposium October 13th 2017 Management of Hepatitis C in Pre- and Post-Transplant Patients Jens Rosenau, MD Associate Professor of Medicine Acting Director
More informationDirect-acting Antiviral (DAA) Regimens in Late-stage Development: Which Patients Should Wait? Fred Poordad, MD
Direct-acting Antiviral (DAA) Regimens in Late-stage Development: Which Patients Should Wait? Fred Poordad, MD The HCV Lifecycle: Multiple Targets Polymerase Inhibitors Protease Inhibitors NS5A Inhibitors
More informationNeed to Assess HCV Resistance to DAAs: Is it Useful and When?
Need to Assess HCV Resistance to DAAs: Is it Useful and When? Stéphane Chevaliez French National Reference Center for Viral Hepatitis B, C and delta Department of Virology & INSERM U955 Henri Mondor Hospital
More informationVirological tools for hepatitis C: re-treatment and resistance. Joop Arends Will Irving. by author
Virological tools for hepatitis C: re-treatment and resistance Joop Arends Will Irving Disclosures Joop Arends Advisory board: Gilead, Abbvie, Janssen, MSD, BMS (research) grants: Abbvie, BMS, MSD and
More informationHepatitis C Resistance Associated Variants (RAVs)
Hepatitis C Resistance Associated Variants (RAVs) Atif Zaman, MD MPH Oregon Health & Science University Professor of Medicine Division of Gastroenterology and Hepatology Nothing to disclose Disclosure
More informationHepatitis C Update: What s New in 2017
Hepatitis C Update: What s New in 2017 Cody A. Chastain, MD Assistant Professor of Medicine Viral Hepatitis Program Division of Infectious Diseases Vanderbilt University Medical Center Cody.a.Chastain@Vanderbilt.edu
More informationHCV therapy : Clinical case
HCV therapy : Clinical case PHC 2018 Paris January 14th, 2018 Tarik Asselah (MD, PhD) Professor of Medicine Hepatology, Chief INSERM UMR 1149, Hôpital Beaujon, Clichy, France. Disclosures Professor Asselah
More informationCase. 63 year old woman now with:
Case 63 year old woman now with: HCV GT 1b, HCV RNA 6.2 x 10 6 IU/mL Asymptomatic except for fatigue Normal exam ALT 72 IU/mL, Bili 0.9 mg/dl, INR 1.1, Albumin 3.9 g/dl, Creatinine 0.7 mg/dl Normal EGD
More informationKristen M. Marks, MD Assistant Professor Weill Cornell Medical College New York, New York
Newly Approved Hepatitis C Virus Drugs: Approach to Initial Therapy Kristen M. Marks, MD Assistant Professor Weill Cornell Medical College New York, New York Learning Objectives After attending this presentation,
More informationHCV Treatment Failure: What Next? Dr Ashley Brown, Imperial College Healthcare NHS Trust, London
HCV Treatment Failure: What Next? Dr Ashley Brown, Imperial College Healthcare NHS Trust, London European HIV Hepatitis Co-infection Conference QEII Conference Centre 10 th December 2015 Dr Ashley Brown
More informationUpdate on Hepatitis C. Francesco Negro Hôpitaux Universitaires de Genève Berne, November 15, 2017
Update on Hepatitis C Francesco Negro Hôpitaux Universitaires de Genève Berne, November 15, 2017 The global prevalence of HCV was 1 0% (95% uncertainty interval 0 8 1 1) in 2015: 71 1 million (62 5 79
More informationHCV Infection: EASL Clinical Practice Guidelines Francesco Negro University Hospital Geneva Switzerland
HCV Infection: EASL Clinical Practice Guidelines 2016 Francesco Negro University Hospital Geneva Switzerland Panel Codinat: Jean-Michel Pawlotsky Panel: Alessio Aghemo David Back Geoffrey Dusheiko Xavier
More informationHCV in 2017: New Therapies and New Opportunities. Presentation prepared by: Date prepared: OBJECTIVES
Project ECHO HCV Collaborative HCV in 217: New Therapies and New Opportunities Paulina Deming, PharmD Assistant Director Hepatitis C Programs, ECHO Institute Associate Professor College of Pharmacy University
More informationDavid L. Wyles, MD Chief, Division of Infectious Disease Denver Health Medical Center Denver, Colorado
FORMATTED: 1/3/16 Drug Resistance-Associated Variants in Hepatitis C Virus Infection: Hype or Help? Atlanta, Georgia: October 2, 216 David L. Wyles, MD Chief, Division of Infectious Disease Denver Health
More informationCurrent HCV Treatment by Genotype
Current HCV Treatment by Genotype Ari Bunim, MD Assistant Professor Clinical Medicine Weill Cornell Medical College Clinical Director of Hepatology New York-Presbyterian/Queens Objectives To understand
More informationHepatitis C Introduction and Overview
Hepatitis C Introduction and Overview Michael S. Saag, MD Professor of Medicine Associate Dean of Global Health Director, Center for AIDS Research University of Alabama at Birmingham Birmingham, Alabama
More informationHepatitis C Genotypes
9/2/21 OBJECTIVES Project ECHO HCV Collaborative HCV in 21: New Therapies and New Opportunities Paulina Deming, PharmD Assistant Director Hepatitis C Programs, ECHO Institute Associate Professor College
More informationHEPATITIS C: UPDATE AND MANAGEMENT
HEPATITIS C: UPDATE AND MANAGEMENT José Franco, MD Professor of Medicine Associate Dean for Educational Improvement Associate Director, Kern Institute STAR Center Director José Franco, MD Disclosures I
More informationCurrent trends in CHC 1st genotype treatment
Current trends in CHC 1st genotype treatment Tarik Asselah MD, PhD Professor of Medicine Hepatology, Chief INSERM UMR 1149, Hôpital Beaujon, Clichy, France Disclosures Employee of Paris Public University
More informationDebate: Do We Need More HCV Drugs Con Standpoint
Debate: Do We Need More HCV Drugs Con Standpoint 18 th Antivirals PK Workshop, Friday 16 th June 2017, Chicago Jürgen Rockstroh Department of Medicine I University Hospital Bonn, Bonn, Germany Conflict
More informationHCV In 2015: Maximizing SVR
HCV In 2015: Maximizing SVR Alnoor Ramji Gastroenterology & Hepatology Clinical Associate Professor Division of Gastroenterology University Of British Columbia ramji_a@hotmail.com Disclosures (within Last
More informationWhat do we need to know about RAVs clinically?
14 th European HIV & Hepatitis Workshop Rome, 25-27 May, 2016 What do we need to know about RAVs clinically? Stefan Zeuzem, MD University of Frankfurt Germany Background Resistance associated variants
More informationTreating Hepatitis C Virus (HCV) Infection
Slide 1 of 42 Treating Hepatitis C Virus (HCV) Infection Susanna Naggie, MD, MHS Associate Professor of Medicine Duke Clinical Research Institute Durham, North Carolina Slide 3 of 42 Learning Objectives
More informationHow to optimize treatment in G3 patients? Jérôme GOURNAY, MD Hépatologie Centre Hospitalier Universitaire de Nantes France
How to optimize treatment in G3 patients? Jérôme GOURNAY, MD Hépatologie Centre Hospitalier Universitaire de Nantes France Paris Hepatitis Conference, January 12, 2016 Disclosures I have received funding
More informationTREATMENT OF GENOTYPE 2
Treatment of Genotype 2, 3,and 4 David E. Bernstein, MD, FACG Advisory Committee/Board Member: AbbVie Pharmaceuticals, Gilead, Merck, Janssen Consultant: AbbVie Pharmaceuticals, Bristol-Myers Squibb, Gilead,
More informationPatients with compensated cirrhosis: how to treat and follow-up
Patients with compensated cirrhosis: how to treat and follow-up Thomas Berg Sektion Hepatologie Klinik und Poliklinik für Gastroenterologie und Rheumatologie Universitätsklinikum Leipzig Leber- und Studienzentrum
More informationUpdates on the AASLD/IDSA HCV Guidance
Updates on the AASLD/IDSA HCV Guidance Susanna Naggie, MD, MHS Associate Professor of Medicine Duke University School of Medicine Durham, North Carolina Learning Objectives After attending this presentation,
More informationSofosbuvir-Velpatasvir-Voxilaprevir in DAA-Experienced GT 1-6 POLARIS-4
Phase 3 Treatment Experienced Sofosbuvir-Velpatasvir-Voxilaprevir in DAA-Experienced GT 1-6 POLARIS-4 Bourlière M, et al. N Engl J Med. 217;376:2134-46. POLARIS-4: Study Features POLARIS-4 Trial Design:
More information10/21/2016. Susanna Naggie, MD, MHS Associate Professor of Medicine Duke University Durham, North Carolina. Learning Objectives
A Crash Course on the AASLD/IDSA Hepatitis C Virus Infection Treatment Guidelines: What s New Susanna Naggie, MD, MHS Associate Professor of Medicine Duke University Durham, North Carolina FORMATTED: 1/3/16
More information10/21/2016. David L. Wyles, MD Chief, Division of Infectious Disease Denver Health Medical Center Denver, Colorado
Drug Resistance-Associated Variants in Hepatitis C Virus Infection: Hype or Help? David L. Wyles, MD Chief, Division of Infectious Disease Denver Health Medical Center Denver, Colorado FORMATTED: 1/3/16
More informationMonitoring Patients Who Are Starting HCV Treatment, Are On Treatment, Or Have Completed Therapy
Monitoring Patients Who Are Starting HCV Treatment, Are On Treatment, Or Have Completed Therapy WV ECHO August 10, 2017 Selection of patients for HCV treatment Despite current guidance to treat everyone,
More informationWhat Should We Do With Difficult to Treat HCV Populations?
What Should We Do With Difficult to Treat HCV Populations? Norah Terrault, MD Professor of Medicine and Surgery Director, Viral Hepatitis Center University of California San Francisco Disclosures Norah
More informationGlecaprevir-Pibrentasvir in HCV GT 1 or 4 & Prior DAA Treatment MAGELLAN-1 (Part 2)
Phase 3 Treatment-Experienced in HCV GT 1 or 4 & Prior DAA Treatment MAGELLAN-1 (Part 2) in HCV GT 1 or 4 & Prior DAA Treatment MAGELLAN-1 (Part 2): Study Features MAGELLAN-1 (Part 2) Trial Design: Randomized,
More informationNew Antivirals for Hep C in Context of HIV: Vosevi and Mavyret
New Antivirals for Hep C in Context of HIV: Vosevi and Mavyret John Scott, MD, MSc, FIDSA November 16, 2017 This presentation is intended for educational use only and does not in any way constitute medical
More informationHCV Treatment of Genotype 1: Now and in the Future
HCV Treatment of Genotype 1: Now and in the Future Bruce R. Bacon, MD, FACG James F. King, MD Endowed Chair in Gastroenterology Professor of Internal Medicine Co-Director of the Abdominal Transplant Program
More information5/12/2016. Learning Objectives. Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients
5/12/216 Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients Alexander Monto, MD Professor of Clinical Medicine University of California San Francisco San Francisco,
More informationTreating HCV Prior to Liver Transplantation. What Are the Treatment Options? Xavier Forns Liver Unit Hospital Clinic, CIBEREHD, IDIBAPS Barcelona
Treating HCV Prior to Liver Transplantation What Are the Treatment Options? Xavier Forns Liver Unit Hospital Clinic, CIBEREHD, IDIBAPS Barcelona Disclosures Unrestricted Grant Support: Janssen and Abbvie
More informationTreatment of HCV infection in daily clinical practice. Which are the optimal options for Genotypes 2 and 3? Jiannis Vlachogiannakos
Treatment of HCV infection in daily clinical practice. Which are the optimal options for Genotypes 2 and 3? Jiannis Vlachogiannakos Associate Professor of Gastroenterology Academic Department of Gastroenterology
More informationTreatment of HCV : 100 % cure?
Treatment of HCV : % cure? PHC 8 PARIS January 5th, 8 Tarik Asselah (MD, PhD) Professor of Medicine Hepatology, Chief ISERM UMR 49, Hôpital Beaujon, Clichy, France. PHC 8 - www.aphc.info Disclosures Employee
More informationCurrent HCV Treatment by Genotype Ira M. Jacobson, MD
Current HCV Treatment by Genotype Ira M. Jacobson, MD Director of Hepatology NYU School of Medicine Objectives To understand the prevalence of HCV and distribution of HCV genotypes Describe the HCV lifecycle
More informationOn Target for Hepatitis C Elimination: Direct Acting Antiviral Agents in 2018
On Target for Hepatitis C Elimination: Direct Acting Antiviral Agents in 2018 Trana Hussaini, PharmD Pharmacotherapy Specialist in Liver Transplantation, VGH Clinical Assistant Professor, Faculty of Pharmaceutical
More informationCase 4: A 61-year-old man with HCV genotype 3 with cirrhosis. Ira M. Jacobson, M.D. Weill Cornell Medical College New York, New York USA
Case 4: A 61-year-old man with HCV genotype 3 with cirrhosis Ira M. Jacobson, M.D. Weill Cornell Medical College New York, New York USA 1 Genotype 3 case 61-year-old man with HCV genotype 3 Cirrhosis on
More informationWhat is the Optimized Treatment Duration? To Overtreat versus Undertreat. Nancy Reau, MD Associate Professor of Medicine University of Chicago
What is the Optimized Treatment Duration? To Overtreat versus Undertreat Nancy Reau, MD Associate Professor of Medicine University of Chicago Learning Objectives: 1. Discuss patient populations appropriate
More informationSaeed Hamid, MD Alex Thompson, MD, PhD
Saeed Hamid, MD Alex Thompson, MD, PhD 1 We will review some top line data from EASL Majority of the time discussing how the data affects daily practice 2 Grazoprevir (GZR; MK-5172) + Elbasvir (EBR; MK-
More informationHCV Treatment Options in 2017/2018: What s Here and What s Coming Soon
HCV Treatment Options in 2017/2018: What s Here and What s Coming Soon Supported by educational grants from AbbVie; Bristol-Myers Squibb; Gilead Sciences; Janssen Therapeutics; Merck & Co., Inc; and ViiV
More informationGenotype 1 HCV in 2016: Clinical Decision Making in a Time of Plenty
Genotype 1 HCV in 216: Clinical Decision Making in a Time of Plenty Ira M. Jacobson, MD Chair, Department of Medicine Mount Sinai Beth Israel Senior Faculty and Vice-Chair, Department of Medicine Icahn
More informationHepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection
Clinical Infectious Diseases IDSA FEATURES Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection AASLD-IDSA HCV Guidance Panel a (See
More informationHIV-HCV Co-Infection in Shobha Swaminathan, MD Associate Professor of Medicine Rutgers New Jersey Medical School
HIV-HCV Co-Infection in 2018 Shobha Swaminathan, MD Associate Professor of Medicine Rutgers New Jersey Medical School AASLD/IDSA and DHHS Guidance: HIV/HCV Coinfection All pts with HIV should be screened
More informationFailure after treatment with DAAs: What to do? Marseille France 2-3 th June 2016
Failure after treatment with DAAs: What to do? Marc Bourliere, MD White Nights of Hepatology Hôpital Saint Joseph Saint Petersburg Marseille France 2-3 th June 16 Disclosures Board member for : Schering-Plough,
More informationSpecial developments in the management of Hepatitis C. Disclosures
Special developments in the management of Hepatitis C Sandeep Mukherjee,MD Division of Gastroenterology CHI Health and Creighton University Medical Center Omaha, NE 68154 Sandeep.Mukherjee@alegent.org
More informationMassimo Puoti SC Malattie Infettive AO Ospedale Niguarda Cà Granda, Milano. Eradicazione da HCV e nuove prospettive: Prospetive Terapeutiche future
Massimo Puoti SC Malattie Infettive AO Ospedale Niguarda Cà Granda, Milano Eradicazione da HCV e nuove prospettive: Prospetive Terapeutiche future DAA classes and subclasses Drug Class Subclass Potency
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Hepatitis C Second Generation Antivirals Page 1 of 32 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: See also: Hepatitis C Second Generation Antivirals Through
More informationIs HCV drug resistance an issue?
Is HCV drug resistance an issue? 5TH ASIAN CONFERENCE ON HEPATITIS&AIDS NANJING, CHINA 28-29 MAY 2016 FROM BASIC SCIENCE TO CLINICAL PRACTIC Jürgen Kurt Rockstroh Department of Medicine I, University Hospital
More informationHCV Drug Resistance: Regulatory Perspective
HCV Drug Resistance: Regulatory Perspective Patrick Harrington, PhD Senior Clinical Virology Reviewer Division of Antiviral Products, FDA/CDER 2016 HIV and Hepatitis Clinical Pharmacology Workshop Washington,
More informationHepatitis C: Newest Treatment Options and What To Do When We Cure It!
Hepatitis C: Newest Treatment Options and What To Do When We Cure It! Richard Kalman, MD Division of Hepatology Department of Transplantation Einstein Medical Center Learning Objectives Scope of HCV How
More informationHepatitis C in Special Populations
Hepatitis C in Special Populations David E. Bernstein, MD, FACG Vice Chairman of Medicine for Clinical Trials Chief, Division of Hepatology and Sandra Atlas Bass Center for Liver Diseases Northwell Health
More informationHCV: The next 18 months. David L. Wyles, M.D. Associate Professor of Medicine UCSD
HCV: The next 18 months David L. Wyles, M.D. Associate Professor of Medicine UCSD FIRST, A LOOK BACK WHAT DID I SAY LAST YEAR? My predictions for genotype 1: Multiple highly efficacious, well-tolerated,
More informationManagement of Chronic HCV 2017 and Beyond
Management of Chronic HCV 2017 and Beyond Blaire E Burman, MD Virginia Mason Gastroenterology & Hepatology Relevant Disclosures No financial disclosures to report Leaning Objectives Burden of HCV Prevalence
More informationSURVEYOR-II Part 2 Study Design
HIGH SVR RATES WITH + CO-ADMINISTERED FOR 8 WEEKS IN NON-CIRRHOTIC PATIENTS WITH HCV GENOTYPE 3 INFECTION A.J. Muir, S. Strasser, S. Wang, S. Shafran, M. Bonacini, P. Kwo, D. Wyles, E. Gane, S.S. Lovell,
More informationHepatitis C in 2018: From Evolution to Revolution
Hepatitis C in 218: From Evolution to Revolution Arthur Y. Kim, MD Associate Professor of Medicine Harvard Medical School Director, Viral Hepatitis Clinic Massachusetts General Hospital Boston, Massachusetts
More informationGlecaprevir-Pibrentasvir in Non-Cirrhotic Genotype 2 ENDURANCE-2
Phase 3 Treatment Naïve or Experienced Glecaprevir-Pibrentasvir in Non-Cirrhotic Genotype 2 ENDURANCE-2 *ENDURANCE-2: Study Features ENDURANCE-2 Trial Design: Randomized, double-blind, placebo-controlled
More informationIntroduction to the Impact of Resistance in Hepatitis C
Introduction to the Impact of Resistance in Hepatitis C Sponsored by AbbVie 2/1/2017 Presented by Sammy Saab, MD, MPH, FACG, AGAF, FAASLD February 1 st, 2017 1 AbbVie disclosures This is an Abbvie sponsored
More information1/16/2019. Goals of HCV Therapy. Objectives. Treating Hepatitis C and HIV Co Infection. Cure Defined as sustained virologic response (SVR)
HCV ECHO WESTERN STATES HCV ECHO WESTERN STATES Treating Hepatitis C and HIV Co Infection Paulina Deming, Pharm D Associate Professor, College of Pharmacy Assistant Director, Viral Hepatitis Programs,
More informationShorter Durations and Pan-genotypic Regimens The Final Frontier. Professor Greg Dore
Shorter Durations and Pan-genotypic Regimens The Final Frontier Professor Greg Dore Disclosures Funding and speaker fees from AbbVie, Bristol-Myers Squibb, Gilead Sciences and Merck Efficacy Evolution
More information10/4/2016. Management of Hepatitis C Virus Genotype 2 or 3 Infection
Management of Hepatitis C Virus Genotype 2 or 3 Infection Kenneth E. Sherman, MD, PHD Gould Professor of Medicine Director, Division of Digestive Diseases University of Cincinnati Cincinnati, Ohio FORMATTED:
More informationA treatment revolution: current management for chronic HCV
A treatment revolution: current management for chronic HCV Ray Chung, M.D. Director of Hepatology and Liver Center Kevin and Polly Maroni Research Scholar Massachusetts General Hospital Disclosures Research
More informationInitial Treatment of HCV G Hugo E. Vargas, MD Professor of Medicine Medical, Director Office of Clinical Research Mayo Clinic Arizona
Initial Treatment of HCV G1 2016 Hugo E. Vargas, MD Professor of Medicine Medical, Director Office of Clinical Research Mayo Clinic Arizona Disclosure Information Disclosure Information Dr. Vargas receives
More informationDrug Class Prior Authorization Criteria Hepatitis C
Drug Class Prior Authorization Criteria Hepatitis C Line of Business: Medicaid P & T Approval Date: Interim (pending P&T approval) Effective Date: July 1, 2018 This policy has been developed through review
More informationDrug Class Prior Authorization Criteria Hepatitis C
Drug Class Prior Authorization Criteria Hepatitis C Line of Business: Medicaid P & T Approval Date: Interim Criteria Pending P&T Approval Effective Date: August 16, 2018 This drug class prior authorization
More informationWhy make this statement?
HCV Council 2014 10 clinical practice statements were evaluated by the Council A review of the available literature was conducted The level of support and level of evidence for the statements were discussed
More informationBaseline and acquired viral resistance to DAAs: how to test and manage
Baseline and acquired viral resistance to DAAs: how to test and manage Round table discussion by Marc Bourliere, Robert Flisiak, Vasily Isakov, Mark Sulkowsky & Konstantin Zhdanov Prevalence of baseline
More informationHepatitis C: New Therapies in
Hepatitis C: New Therapies in 216-217 Mark Sulkowski, MD Professor of Medicine Johns Hopkins University School of Medicine Medical Director, Viral Hepatitis Center Divisions of Infectious Diseases and
More informationDisclosures. I have given sponsored lectures for the following pharmaceutical companies: Gilead, Abbvie and MSD. I own shares of Gilead Sciences.
Disclosures I have given sponsored lectures for the following pharmaceutical companies: Gilead, Abbvie and MSD. I own shares of Gilead Sciences. Chronic Hepatitis C Prof CL Lai University Department of
More informationTreatment of HCV in 2016
5/1/16 Treatment of HCV in 16 Graham R Foster Professor of Hepatology QMUL Conflicts of Interest Speaker and consultancy fees received from AbbVie, BI, BMS, Gilead, Janssen, Roche, Merck, Novartis, Springbank,
More informationHCV Resistance Associated variants: impact on chronic hepatitis C treatment
HCV Resistance Associated variants: impact on chronic hepatitis C treatment Dr. Stéphane Chevaliez Associate Professor of Medicine at the University of Paris-Est. History of Resistance in HCV Concern Only
More informationUniversal HCV treatment: Strategies for simplification
Universal HCV treatment: Strategies for simplification PARIS HEPATOLOGY CONFERENCE 3 January 217 Tarik Asselah (MD, PhD) Hepatology & Chief INSERM UMR 1149, Hôpital Beaujon, Clichy, France. Disclosures
More informationHepatitis C Prior Authorization Policy
Hepatitis C Prior Authorization Policy Line of Business: Medi-Cal P&T Approval Date: November 15, 2017 Effective Date: January 1, 2018 This policy has been developed through review of medical literature,
More informationHCV Screening, Management, and Treatment Guidelines
HCV ECHO WESTERN STATES HCV Screening, Management, and Treatment Guidelines Paulina Deming, PharmD, PhC Associate Professor of Pharmacy-College of Pharmacy Project ECHO University of New Mexico Health
More informationTreatment of Unique Populations Raymond T. Chung, MD
Treatment of Unique Populations Raymond T. Chung, MD Director of Hepatology and Liver Center Vice Chief, Gastroenterology Kevin and Polly Maroni Research Scholar Mass General Hospital Disclosures Research
More informationPIB. Next Generation Direct-Acting Antivirals. Collectively: G/P. Pibrentasvir (formerly ABT-530) pangenotypic NS5A inhibitor
Surveyor-II, Part 3: Efficacy and Safety of Glecaprevir/Pibrentasvir (Abt-493/Abt-53) in Patients with Hepatitis C Virus Genotype 3 Infection with Prior Treatment Experience and/or Cirrhosis David L. Wyles,
More informationUpdate in the Management of Hepatitis C: What Does the Future Hold
Update in the Management of Hepatitis C: What Does the Future Hold Paul Y Kwo, MD, FACG Professor of Medicine Mdi Medical ldirector, Liver Transplantation tti Gastroenterology/Hepatology Division Indiana
More informationHepatitis C Virus: HIV/Hepatitis C Coinfection Wednesday, August 24, 2016
Hepatitis C Virus: HIV/Hepatitis C Coinfection Debika Bhattacharya, MD, MSc Associate Clinical Professor University of California Los Angeles Los Angeles, California Washington, DC: August 24, 2016 Slide
More informationExpert Perspectives: Best of HCV from EASL 2015
Best of HCV from EASL 2015 Expert Perspectives: Best of HCV from EASL 2015 Saeed Hamid, MD Alex Thompson, MD, PhD This activity is supported by educational grants from AbbVie, Bristol-Myers Squibb, and
More informationManagement of HCV in Decompensated Liver Disease
Management of HCV in Decompensated Liver Disease Michael P. Manns Hannover Medical School (MHH) Department of Gastroenterology, Hepatology and Endocrinology Helmholtz Center for Infection Research (HZI),
More informationHCV Treatment in 2016
HCV Treatment in 2016 Hugo E. Vargas, MD Professor of Medicine Mayo College of Medicine Medical Director, Clinical Trials Office Vice Chair, Department of Research Educational Goals Caveats: Cannot cover
More informationHARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES
HARVARD PILGRIM HEALTH CARE Generic Brand HICL GCN Exception/Other DACLATASVIR DAKLINZA 41377 ELBASVIR/GRAZOPREVIR ZEPATIER 43030 GLECAPREVIR/PIBRENTASVIR MAVYRET 44453 OMBITASVIR/PARITAPREVIR/ RITONAVIR
More informationManagement of HIV/HCV Coinfection. Kristen M. Marks, MD Assistant Professor Weill Cornell Medical College New York, NY
Management of HIV/HCV Coinfection Kristen M. Marks, MD Assistant Professor Weill Cornell Medical College New York, NY Disclosure Dr. Marks has received grants and research support from Gilead Sciences
More informationInitial Treatment of the Hepatitis C Virus-Infected Patient
IDSA/AASLD www.hcvguidelines.org http://www.easl.eu/research/our-contributions/clinical-practice-guidelines/detail/easl-recommendations-ontreatment-of-hepatitis-c-216 Initial Treatment of the Hepatitis
More informationTHE THERAPEUTIC REVOLUTION THAT TRANSFORMED CHRONIC HEPATITIS C TO A CURABLE DISEASE
THE THERAPEUTIC REVOLUTION THAT TRANSFORMED CHRONIC HEPATITIS C TO A CURABLE DISEASE MARIA SCHINA CONSULTANT PHYSICIAN INTERNAL MEDICINE AND HEPATOLOGY ATHENS EUROCLINIC 10 th INTERNATIONAL CONGRESS OF
More informationHCV Update from AASLD 2016
HCV Update from AASLD 2016 Ahmed Elsharkawy Consultant Hepatologist QE Birmingham Secretary and Chair-Elect of BVHG BHIVA/BVHG Feedback Meeting November 2016 Speaker Name Ahmed Elsharkawy Statement Speaking
More informationGlecaprevir and Pibrentasvir in HCV GT 1-6 without Cirrhosis SURVEYOR-I and SURVEYOR-II
Phase 3 Treatment-Naïve and Treatment-Experienced Glecaprevir and Pibrentasvir in HCV GT 1-6 without Cirrhosis SURVEYOR-I and SURVEYOR-II Glecaprevir and Pibrentasvir in HCV GT 1-6 without Cirrhosis SURVEYOR-I
More informationMavyret (glecaprevir/pibrentasvir)
(glecaprevir/pibrentasvir) Override(s) Prior Authorization Quantity Limit Medication (glecaprevir/pibrentasvir) Approval Duration Based on Genotype, Treatment Status, or Cirrhosis Status. Quantity Limit
More informationChronic Hepatitis C Drug Class Prior Authorization Protocol
Line of Business: Medi-Cal Effective Date: August 16, 2017 Revision Date: August 16, 2017 Chronic Hepatitis C Drug Class Prior Authorization Protocol This policy has been developed through review of medical
More information